Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
Hematologists discussed the still limited treatment options for sickle cell disease at ASH, weighing the risks and benefits of disease-modifying versus curative therapies after the withdrawal of Pfizer’s Oxbryta (voxelotor).
US firm is using a mix of partnerships and direct presence to build its operations in Asia, which will focus on novel drugs.
BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.
While Pfizer’s analysts’ meeting cheered its investors with clear guidance, Novo Nordisk presented disappointing obesity data. The true value of CagriSema cannot be estimated without more information, however.
BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.
The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.
While Pfizer’s analysts’ meeting cheered its investors with clear guidance, Novo Nordisk presented disappointing obesity data. The true value of CagriSema cannot be estimated without more information, however.
With loss of exclusivity for Opdivo looming in 2028, Opdivo Qvantig will help BMS retain at least some of the revenue for its brand-name blockbuster after biosimilars for the I.V. version hit in 2029.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
While Pfizer’s analysts’ meeting cheered its investors with clear guidance, Novo Nordisk presented disappointing obesity data. The true value of CagriSema cannot be estimated without more information, however.
Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
